Detalles de la búsqueda
1.
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data.
Liver Int
; 43(8): 1803-1812, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37452505
2.
Platinum sensitivity in patients with IDH1/2 mutated vs wild-type intrahepatic cholangiocarcinoma: A propensity score-based study.
Int J Cancer
; 151(8): 1310-1320, 2022 10 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35723131
3.
Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib.
Hepatol Res
; 51(7): 796-802, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-34005839
4.
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab.
Target Oncol
; 19(2): 223-235, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38345693
5.
Incidence and Predictors of Esophagogastric Varices Bleeding in Patients with Hepatocellular Carcinoma in Lenvatinib.
Liver Cancer
; 13(2): 215-226, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38751557
6.
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study.
Target Oncol
; 19(3): 359-370, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38691295
7.
Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience.
Ther Adv Med Oncol
; 15: 17588359231171574, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37457302
8.
Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers.
Clin Cancer Res
; 29(23): 4853-4862, 2023 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37773629
9.
Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients.
Target Oncol
; 18(1): 139-145, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36689074
10.
Advances in pharmacotherapy for cholangiocarcinoma: from conventional therapies to targeted drugs.
Expert Opin Pharmacother
; 23(4): 473-481, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34964678
11.
Determinants of Treatment Benefit and Post-Treatment Survival for Patients with Hepatocellular Carcinoma Enrolled in Second-Line Trials after the Failure of Sorafenib Treatment.
J Pers Med
; 12(10)2022 Oct 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-36294865
12.
Simultaneous Care in Oncology: A 7-Year Experience at ESMO Designated Centre at Veneto Institute of Oncology, Italy.
Cancers (Basel)
; 14(10)2022 May 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-35626172
13.
Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study.
Eur J Cancer
; 166: 165-175, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35303508
14.
The oncological multidimensional prognostic index is a promising decision-making tool: A real-world analysis in older patients with metastatic colorectal cancer.
Eur J Cancer
; 177: 112-119, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36335781
15.
Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma.
Sci Rep
; 12(1): 18775, 2022 11 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36335135
16.
Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1-mutated clusters.
Eur J Cancer
; 175: 299-310, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36182816
17.
Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis.
J Cancer Res Clin Oncol
; 147(12): 3665-3671, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-33745079
18.
Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience.
Target Oncol
; 16(5): 653-661, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34491510
19.
Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis.
Target Oncol
; 16(3): 401-410, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33646487
20.
Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases.
JCO Precis Oncol
; 52021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34327297